Though we have selected pBPB based on our earlier findings in the asthma study [21,22], there are newer pharmaceutical agents like varespladib (LY315920) and its prodrug methyl-varespladib (LY333013) that had shown very effective sPLA2 inhibition even at nanomolar concentrations [81,82], which should be explored for their anti-fibrotic activities in lung fibrosis in future. This evidence concerns the gene PLA2G2A and pulmonary fibrosis.